N,N-二甲基对苯二胺硫酸盐 | 6219-73-4

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N-二甲基对苯二胺硫酸盐
• 中文别名: N,N-二甲基-P-苯二胺硫酸盐；N,N-二甲基对苯二胺二硫酸盐；对氨基-N,N-二甲基苯胺硫酸盐；N,N-二甲基-1,4-苯二胺硫酸盐；4-氨基-N,N-二甲基苯胺硫酸盐；硫酸对氨基二甲苯胺；N,N-二甲基对苯二胺,硫酸盐
• 英文名称: N,N-dimethyl-p-phenylenediamine sulfate
• 英文别名: N,N-dimethyl-1,4-phenylenediamine sulfate；N,N-dimethyl-p-phenylenediammonium sulfate；(4-azaniumylphenyl)-dimethylazanium;sulfate
• CAS: 6219-73-4
• 化学式: C₈H₁₂N₂*H₂O₄S
• 分子量: 234.276
• InChiKey: GLUKPDKNLKRLHX-UHFFFAOYSA-N

物化性质

• 熔点：
  200-205 °C (dec.)(lit.)
• 沸点：
  495 °C(lit.)
• 稳定性/保质期：
  - 常温常压下稳定。 - 吸入、口服或接触皮肤均有毒性，大量使用时应穿戴适当的防护装备。

计算性质

• 辛醇/水分配系数(LogP)：
  0.68
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1(a)
• 危险品标志：
  T
• 危险类别码：
  R23/24/25,R36/37/38
• 危险品运输编号：
  UN 2811 6.1/PG 2
• WGK Germany：
  3
• 包装等级：
  II
• 危险类别：
  6.1(a)
• 安全说明：
  S26,S36/37/39,S45

SDS

Name:	N N-Dimethyl-P-Phenylenediamine Sulfate 99% (Titr.) Material Safety Data Sheet
Synonym:	1,4-Benzenediamine, N,N-Dimethyl-, Sulfate
CAS:	6219-73-4

Section 1 - Chemical Product MSDS Name:N N-Dimethyl-P-Phenylenediamine Sulfate 99% (Titr.) Material Safety Data Sheet
Synonym:1,4-Benzenediamine, N,N-Dimethyl-, Sulfate

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6219-73-4	1,4-Benzenediamine, N,N-Dimethyl-, Sul	98	228-292-7

Hazard Symbols: T
Risk Phrases: 23/24/25

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Toxic by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Containers may explode when heated. Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes.
Extinguishing Media:
Do NOT get water inside containers. For small fires, use dry chemical, carbon dioxide, or water spray. For large fires, use water spray, fog or regular foam. Cool containers with flooding quantities of water until well after fire is out.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6219-73-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige to gray
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 495 deg C @ 760.00mm Hg
Freezing/Melting Point: 234.00 - 236.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12N2.H2SO4
Molecular Weight: 234.28

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide, hydrogen sulfide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6219-73-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,4-Benzenediamine, N,N-Dimethyl-, Sulfate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: DYE, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3143
Packing Group: II
IMO
Shipping Name: DYE, SOLID, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3143
Packing Group: II
RID/ADR
Shipping Name: DYE, SOLID, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3143
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T
Risk Phrases:
R 23/24/25 Toxic by inhalation, in contact with skin
and if swallowed.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 24/25 Avoid contact with skin and eyes.
S 28 After contact with skin, wash immediately
with...
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6219-73-4: No information available.
Canada
CAS# 6219-73-4 is listed on Canada's DSL List.
CAS# 6219-73-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6219-73-4 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

检测水中游离氯和溴、铊盐、过氧化氢、氧化酶、臭氧、胱氨酸、丙酮、脲酸和钒的试剂，比色测定硫化氢和硫化物的试剂，滴定钡盐时作指示剂，测定微量硫的试剂。

用途

1. 检测水中游离氯和溴、铊盐、过氧化氢、氧化酶、臭氧、胱氨酸、丙酮、脲酸和钒。
2. 比色测定硫化氢和硫化物。
3. 滴定钡盐时作指示剂。
4. 测定微量硫。

反应信息

• 作为反应物：
  描述：

  N,N-二甲基对苯二胺硫酸盐 在 potassium dichromate 、 aluminum(III) sulphate octadecahydrate 、 sodium thiosulfate 、 zinc(II) chloride 作用下， 以 水 为溶剂， 反应 2.5h， 以49%的产率得到2-amino-5-dimethylaminophenylthiosulphonic acid
  参考文献：
  名称：

  吩噻嗪鎓光敏剂XI。改进的甲苯胺蓝光抗菌剂

  摘要：

  吩噻嗪鎓衍生物甲苯胺蓝O（TBO）在临床试验中，特别是在牙科领域中，广泛用作光抗菌剂。但是，其对一系列致病微生物物种的活性与标准的光抗菌亚甲蓝没有明显不同。在当前的研究中，通过建立的苯胺硫磺路线，使用温和的氧化剂碳酸银（II）保留取代基，合成了在生色团2位上的烃取代基不同的TBO衍生物。 所得的类似物系列证明了预期的可见吸收波长和亲脂性随烃含量的增加而增加，以及具有更大取代基的衍生物的聚集减少，并且在体外照射下所有这些产生单线态氧。相对于母体化合物，针对一系列与感染控制相关的细菌和真菌病原体进行的筛选显示，其活性显着提高，尤其是针对临床上重要的革兰氏阴性细菌铜绿假单胞菌。另外，为了证明临床相关性，将新衍生物对微生物靶标的光活性与常规的抗菌和抗真菌药以及通常用于局部消毒的杀菌剂进行了比较。相对于局部消毒剂，此处的活性通常也大于用于比较的常规试剂的活性。

  DOI：

  10.1016/j.jphotobiol.2016.03.035
• 作为试剂：
  描述：

  麦角硫因 在 ergothionase gene 、 gene encoding the DUF₉₁₇ family protein 、 thiourocanate hydratase gene 、 盐酸 、 iron(III) chloride 、 N,N-二甲基对苯二胺硫酸盐 作用下， 以 水 为溶剂， 反应 1.33h， 生成 (试剂)3-(2,5-DIOXOIMIDAZOLIDIN-4-YL)PROPANOIC ACID
  参考文献：
  名称：

  在伯克霍尔德菌中鉴定编码 3-(5-oxo-2-thioxoimidazolidin-4-yl) 丙酸脱硫酶的基因。HME13.

  摘要：

  在这里，我们报告了在伯克霍尔德菌属中编码一种新型酶 3-(5-oxo-2-thioxoimidazolidin-4-yl) 丙酸脱硫酶的基因的鉴定。HME13. 该酶将 3-(5-oxo-2-thioxoimidazolidin-4-yl) 丙酸和 H2O 转化为 3-(2,5-dioxoimidazolidin-4-yl) 丙酸和 H2S。该酶的氨基酸序列分析表明它属于 DUF917 蛋白家族，该家族由功能未知的蛋白质组成。

  DOI：

  10.1093/bbb/zbaa066

文献信息

• [EN] TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS<br/>[FR] DÉRIVÉS DE BLEU DE TOLUIDINE UTILISÉS EN TANT QUE COMPOSÉS DE PHOTOSENSIBILISATION
  申请人：PHARMALUCIA LTD

  公开号：WO2011114137A1

  公开（公告）日：2011-09-22

  A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.

  一种化合物的化学式（III），或其药学上可接受的衍生物，用于抗击和/或检测病原体和/或肿瘤细胞的方法；其中X从O、S和Se中选择；R2、R3和R4中的每一个独立地从氢或可选择取代的烷基、烯基、炔基或芳基中选择；R1从卤素、磺酰、酰基、磺氧基、巯基、硝基、氨基、羟基或可选择取代的烷基、烯基、炔基、芳基、胺基或烷氧基中选择；其中当R3和R4中的每一个是甲基或氢时，R1不是甲基或氢。
• TOLUIDINE BLUE DERIVATIVES AS PHOTOSENSITISING COMPOUNDS
  申请人：Wainwright Mark

  公开号：US20120328530A1

  公开（公告）日：2012-12-27

  A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R 2 , R 3 and R 4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R 1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R 1 is not methyl or hydrogen when each of R 3 and R 4 is methyl or hydrogen.

  公式（III）的化合物，或其药学上可接受的衍生物，用于对抗和/或检测病原体和/或肿瘤细胞的方法；其中X从O、S和Se中选择；R2、R3和R4中的每一个独立地选择自氢或一个可选择地取代的烷基、烯基、炔基或芳基；R1从卤素、磺酰、酰基、磺氧基、巯基、硝基、氨基、羟基或一个可选择地取代的烷基、烯基、炔基、芳基、胺基或烷氧基中选择；其中当R3和R4中的每一个是甲基或氢时，R1不是甲基或氢。
• [EN] CYSTATHIONINE-Y-GAMMA-LYASE (CSE) INHIBITORS<br/>[FR] INHIBITEURS DE LA CYSTATHIONINE-Y-GAMMA-LYASE (CSE)
  申请人：SOVA PHARMACEUTICALS INC

  公开号：WO2014018569A1

  公开（公告）日：2014-01-30

  Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ- lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

  本文描述了抑制半胱氨酸-γ-裂解酶（CSE）的化合物和含有这些化合物的药物组合物。本文还描述了使用这些CSE抑制剂的方法，单独或与其他化合物结合，用于治疗需要CSE抑制的疾病或症状。
• [EN] ACRYLATE-FUNCTIONAL BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COPOLYMER FORMED THEREWITH<br/>[FR] COMPOSÉ D'ORGANOSILICIUM RAMIFIÉ À FONCTION ACRYLATE, SON PROCÉDÉ DE PRÉPARATION ET COPOLYMÈRE FORMÉ AVEC CELUI-CI
  申请人：DOW SILICONES CORP

  公开号：WO2020142474A1

  公开（公告）日：2020-07-09

  A method of preparing an acrylate-functional branched organosilicon compound ("compound") is provided, and comprises reacting (A) a branched organosilicon compound and (B) an acrylate compound in the presence of (C) a catalyst, wherein component (A) has the general formula X-Si(R1)3, where X comprises a halogen-functional moiety and each R1 is selected from R and –OSi(R4)3, with the proviso that at least one R1 is –OSi(R4)3; each R4 is selected from R, –OSi(R5)3, and –[OSiR2]mOSiR3; each R5 is selected from R, –OSi(R6)3, and –[OSiR2]mOSiR3; each R6 is selected from R and –[OSiR2]mOSiR3; each R is an independently selected hydrocarbyl group; and 0≤m≤100; with the proviso that at least one of R4, R5 and R6 is –[OSiR2]mOSiR3. The compound prepared by the method, a copolymer comprising the reaction product of the compound and a second compound, a method of forming the copolymer, and a composition comprising the copolymer are each also provided.

  提供了一种制备丙烯酸酯官能化分支有机硅化合物（“化合物”）的方法，包括在催化剂存在下，使（A）分支有机硅化合物和（B）丙烯酸酯化合物发生反应，其中组分（A）具有一般式X-Si（R1）3，其中X包括卤素官能基，每个R1从R和–OSi（R4）3中选择，但至少一个R1为–OSi（R4）3；每个R4从R、–OSi（R5）3和–[OSiR2]mOSiR3中选择；每个R5从R、–OSi（R6）3和–[OSiR2]mOSiR3中选择；每个R6从R和–[OSiR2]mOSiR3中选择；每个R是独立选择的烃基；且0≤m≤100；但至少一个R4、R5和R6为–[OSiR2]mOSiR3。还提供了通过该方法制备的化合物，包括化合物和第二化合物的反应产物的共聚物，形成共聚物的方法，以及包含共聚物的组合物。
• Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction
  申请人：ZHU YIZHUN

  公开号：US20090036534A1

  公开（公告）日：2009-02-05

  A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier.

  揭示了一种用于治疗受试者心肌梗死的药物组合物及其制备和应用方法。该药物组合物包括从SEC、SPC、SBC、SPEC、SAC、SAMC和SPRC等化合物组合中选择的至少一种合成化合物的治疗有效量，以及一种药用可接受的载体。

表征谱图